Phospholipid conjugate for intracellular delivery of peptide nucleic acids.
Peptide nucleic acids (PNAs) have a number of attractive features that have made them an ideal choice for antisense and antigene-based tools, probes, and drugs, but their poor membrane permeability has limited their application as therapeutic or diagnostic agents. Herein, we report a general method for the synthesis of phospholipid-PNAs (LP-PNAs) and compare the effect of noncleavable lipids and bioreductively cleavable lipids (L and LSS) and phospholipid (LP) on the splice-correcting bioactivity of a PNA bearing the cell penetrating Arg9 group (PNA-R9). While the three constructs show similar and increasing bioactivity at 1-3 microM, the activity of LP-PNA-R9 continues to increase from 4-6 microM, while the activity of L-PNA-R9 remains constant and that of LSS-PNA-R9 decreases rapidly in parallel with their relative cytotoxicity. The activity of both LP-PNA-R9 and L-PNA-R9 dramatically increased in the presence of chloroquine, as expected for an endocytotic entry mechanism. The constructs were also found to have CMC values of 1.0 and 4.5 microM, respectively, in 150 mM NaCl, pH 7 water, suggesting that micelle formation may play a hitherto unrecognized role in modulating toxicity and/or facilitating endocytosis.
Shen
Gang
G
Department of Chemistry, Washington University in St. Louis, St. Louis, Missouri 63130, USA.
Fang
Huafeng
H
Song
Yinyin
Y
Bielska
Agata A
AA
Wang
Zhenghui
Z
Taylor
John-Stephen A
JS
D000818:Animals; D016923:Cell Death; D002460:Cell Line; D002463:Cell Membrane Permeability; D002738:Chloroquine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers / Q000138:chemical synthesis* / Q000493:pharmacokinetics; D016503:Drug Delivery Systems; D006801:Humans; D008823:Micelles; D020135:Peptide Nucleic Acids / Q000737:chemistry* / Q000493:pharmacokinetics; D010743:Phospholipids / Q000737:chemistry* / Q000493:pharmacokinetics; D013329:Structure-Activity Relationship
D004337:Drug Carriers; D008823:Micelles; D020135:Peptide Nucleic Acids; D010743:Phospholipids; D002738:Chloroquine
Biochemistry. 1998 May 5;37(18):6235-9
9572837
Oncogene. 2005 Aug 4;24(33):5262-8
15940257
Bioconjug Chem. 2008 Sep;19(9):1880-7
18690739
Bioconjug Chem. 2006 May-Jun;17(3):750-8
16704214
Expert Opin Biol Ther. 2007 Jul;7(7):1021-34
17665991
J Control Release. 2006 Feb 21;110(3):595-604
16377019
Appl Microbiol Biotechnol. 2006 Aug;71(5):575-86
16683135
Nucleic Acids Res. 2008 Nov;36(20):6418-28
18842625
Pharm Res. 2007 Jan;24(1):1-16
17109211
Science. 1991 Dec 6;254(5037):1497-500
1962210
Mol Pharm. 2009 Mar-Apr;6(2):615-26
19231840
Curr Med Chem. 2005;12(22):2561-99
16248816
Oligonucleotides. 2006 Spring;16(1):43-57
16584294
Curr Top Med Chem. 2005;5(12):1119-31
16248787
J Pept Res. 2000 Nov;56(5):318-25
11095185
J Control Release. 2000 Aug 10;68(2):237-49
10925132
Biochemistry. 2007 Jun 26;46(25):7581-9
17536840
Curr Pharm Biotechnol. 2007 Oct;8(5):291-304
17979727
Bioconjug Chem. 2008 Aug;19(8):1526-34
18646838
Cancer Res. 2008 May 1;68(9):3370-8
18451164
Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12200-5
18723668
Chem Biol. 1999 Jun;6(6):343-51
10375543
Nat Rev Mol Cell Biol. 2008 Aug;9(8):639-49
18612320
Nat Protoc. 2006;1(2):633-6
17406290
Methods. 2001 Feb;23(2):97-107
11181029
Curr Top Med Chem. 2008;8(15):1379-404
18991725
Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13003-8
11087855
Bioconjug Chem. 2008 Nov 19;19(11):2196-204
18831575
Mol Biotechnol. 2004 Mar;26(3):233-48
15004293
Int J Pharm. 2007 Nov 1;344(1-2):96-102
17600642
Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6460-5
16608910
Langmuir. 1985 May;1(3):352-5
21370917
Adv Genet. 2006;56:1-51
16735154
Nucleic Acids Res. 2007;35(13):4495-502
17584792
Methods Mol Biol. 2002;208:211-23
12229290
Chem Biol. 2001 Feb;8(2):199-205
11251293
J Med Chem. 2006 Nov 2;49(22):6522-31
17064070
Antisense Nucleic Acid Drug Dev. 2002 Apr;12(2):51-63
12074365
Breast Cancer Res Treat. 2006 Mar;96(1):73-81
16319992
J Control Release. 2006 Aug 10;114(1):100-9
16831482